Sanofi-aventis and Bristol-Myers Squibb (BMS) announced the European approval of their dual antiplatelet combination tablet DuoPlavin/DuoCover (clopidogrel 75mg and acetylsalicylic acid 100mg or 75 mg) by the European Commission.
DuoPlavin/DuoCover is indicated for the prevention of atherothrombotic events in adult patients already taking both clopidogrel and acetylsalicylic acid (ASA). It is a fixed dose combination medicinal product for continuation of therapy in non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction) including patients undergoing a stent placement following percutaneous coronary intervention and for the treatment of ST-segment elevation acute myocardial infarction in medically treated patients eligible for thrombolytic therapy.
Robust evidence from large clinical studies has led to the approval and use of Plavix 75mg in combination with acetylsalicylic acid (75mg-325mg).
The new formulation of DuoPlavin/DuoCover carrying both these antiplatelets in one single tablet contributes to reducing daily pill burden for patients.
DuoPlavin is indicated for the prevention of atherothrombotic events in adult patients already taking both clopidogrel and acetylsalicylic acid (ASA). DuoPlavin is a fixed-dose combination medicinal product for continuation of therapy in: 1. Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction) including patients undergoing a stent placement following percutaneous coronary intervention. 2. ST segment elevation acute myocardial infarction in medically treated patients eligible for thrombolytic therapy.
Plavix is recommended daily for patients who have had a recent heart attack or stroke, or poor circulation in the legs that may cause pain during exercise, such as walking, and may be relieved by rest (known as peripheral artery disease, or P.A.D.). Plavix is also recommended in addition to ASA for patients who have been hospitalized with heart-related chest pain (unstable angina) or had a heart attack.
Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes
therapeutic solutions to improve the lives of everyone.
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.